Literature DB >> 25203034

Patents or patients: who loses?

Joanna Brougher, Konstantin M Linnik1.   

Abstract

The unprecedented weakening of patent rights in the United States undermines necessary incentives for the discovery and development of innovative medicines.

Entities:  

Mesh：

Year:  2014        PMID： 25203034     DOI： 10.1038/nbt.3005

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  3 in total

1.  Using market-exclusivity incentives to promote pharmaceutical innovation.

Authors:  Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2010-11-04       Impact factor: 91.245

2.  Merck KGaA v. Integra Lifesciences I, Ltd: implications of the supreme court's decision for the people who matter most...the consumer.

Authors:  Ian Jaquette
Journal:  Am J Law Med       Date:  2007

Review 3.  Follow-on biologics: data exclusivity and the balance between innovation and competition.

Authors:  Henry Grabowski
Journal:  Nat Rev Drug Discov       Date:  2008-05-12       Impact factor: 84.694
  3 in total
  2 in total

1.  Exploring the role of R&D collaborations and non-patent IP policies in government technology transfer performance: Evidence from U.S. federal agencies (1999-2016).

Authors:  Iman Hemmatian; Todd A Ponzio; Amol M Joshi
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

Review 2.  An Elucidative Review to Analytically Sieve the Viability of Nanomedicine Market.

Authors:  Anaida Kad; Archit Pundir; Shailendra Kumar Arya; Neha Bhardwaj; Madhu Khatri
Journal:  J Pharm Innov       Date:  2020-09-21       Impact factor: 2.538
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.